Assessing Bladder Cancer Risk in Type 2 Diabetes Clinical Trials: the Dapagliflozin Drug Development Program as a ‘Case Study’

Agata Ptaszynska, Samuel Monroe Cohen, Edward M. Messing, Timothy P. Reilly, Eva Johnsson, Kristina Johnsson

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Introduction: Dapagliflozin, a sodium-glucose co-transporter 2 inhibitor, decreases plasma glucose levels by suppressing renal glucose reabsorption and increasing urinary glucose excretion. Previously published pre-clinical data suggest that dapagliflozin lacks carcinogenic potential. This article reviews data on bladder cancer with dapagliflozin to illustrate the challenges in assessing bladder cancer in drug development programs in patients with type 2 diabetes mellitus (T2DM). Methods: Clinical cases of bladder cancer were analyzed in a pooled population of >9000 patients in 21 phase 2b/3 dapagliflozin clinical trials of up to 208 weeks’ duration. Results: In the 21-study pool, demographic and baseline characteristics were generally consistent between dapagliflozin and comparator groups. The overall incidence of malignancies was also balanced between the treatment groups, with an incidence rate ratio (IRR) of 1.035 [95% confidence interval (CI): 0.724, 1.481]. Nine of 5936 dapagliflozin-treated patients and 1 of 3403 comparator-treated patients reported bladder cancer, with an IRR of 5.168 (95% CI: 0.677, 233.55). All of these patients had clinical attributes typical of bladder cancer in the general population (≥60-year-old males; 8 of the 10 patients were current/former smokers). All cases of bladder cancer were reported within 2 years of starting study treatment. There was an absence of detailed workup of hematuria prior to randomization, and no hematuria workup data were collected proactively in the dapagliflozin trials, which is typical of clinical practice. Failure to exclude bladder cancer prior to randomization increases the chance of recruiting patients with pre-existing bladder cancer in clinical trials and may delay the final diagnosis. Of the nine dapagliflozin-treated patients with bladder cancer, eight had microscopic hematuria prior to start of treatment or within 6 months of initiating study treatment. Conclusion: The assessment of bladder cancer data illustrates the challenges of characterizing cancer risk in T2DM drug development programs. The totality of evidence to date does not suggest a causal relationship between dapagliflozin and bladder cancer. Funding: AstraZeneca.

Original languageEnglish (US)
Pages (from-to)357-375
Number of pages19
JournalDiabetes Therapy
Volume6
Issue number3
DOIs
StatePublished - Sep 26 2015

Fingerprint

Urinary Bladder Neoplasms
Type 2 Diabetes Mellitus
Clinical Trials
Pharmaceutical Preparations
Hematuria
Random Allocation
Glucose
Sodium-Glucose Transporter 2
Incidence
2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol
Confidence Intervals
Symporters
Therapeutics
Population
Neoplasms
Demography

Keywords

  • Bladder cancer
  • Dapagliflozin
  • Hematuria
  • SGLT2 inhibitor
  • Type 2 diabetes mellitus

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Assessing Bladder Cancer Risk in Type 2 Diabetes Clinical Trials : the Dapagliflozin Drug Development Program as a ‘Case Study’. / Ptaszynska, Agata; Cohen, Samuel Monroe; Messing, Edward M.; Reilly, Timothy P.; Johnsson, Eva; Johnsson, Kristina.

In: Diabetes Therapy, Vol. 6, No. 3, 26.09.2015, p. 357-375.

Research output: Contribution to journalArticle

Ptaszynska, Agata ; Cohen, Samuel Monroe ; Messing, Edward M. ; Reilly, Timothy P. ; Johnsson, Eva ; Johnsson, Kristina. / Assessing Bladder Cancer Risk in Type 2 Diabetes Clinical Trials : the Dapagliflozin Drug Development Program as a ‘Case Study’. In: Diabetes Therapy. 2015 ; Vol. 6, No. 3. pp. 357-375.
@article{26d75394d8c24288bdce9b534eaedcc7,
title = "Assessing Bladder Cancer Risk in Type 2 Diabetes Clinical Trials: the Dapagliflozin Drug Development Program as a ‘Case Study’",
abstract = "Introduction: Dapagliflozin, a sodium-glucose co-transporter 2 inhibitor, decreases plasma glucose levels by suppressing renal glucose reabsorption and increasing urinary glucose excretion. Previously published pre-clinical data suggest that dapagliflozin lacks carcinogenic potential. This article reviews data on bladder cancer with dapagliflozin to illustrate the challenges in assessing bladder cancer in drug development programs in patients with type 2 diabetes mellitus (T2DM). Methods: Clinical cases of bladder cancer were analyzed in a pooled population of >9000 patients in 21 phase 2b/3 dapagliflozin clinical trials of up to 208 weeks’ duration. Results: In the 21-study pool, demographic and baseline characteristics were generally consistent between dapagliflozin and comparator groups. The overall incidence of malignancies was also balanced between the treatment groups, with an incidence rate ratio (IRR) of 1.035 [95{\%} confidence interval (CI): 0.724, 1.481]. Nine of 5936 dapagliflozin-treated patients and 1 of 3403 comparator-treated patients reported bladder cancer, with an IRR of 5.168 (95{\%} CI: 0.677, 233.55). All of these patients had clinical attributes typical of bladder cancer in the general population (≥60-year-old males; 8 of the 10 patients were current/former smokers). All cases of bladder cancer were reported within 2 years of starting study treatment. There was an absence of detailed workup of hematuria prior to randomization, and no hematuria workup data were collected proactively in the dapagliflozin trials, which is typical of clinical practice. Failure to exclude bladder cancer prior to randomization increases the chance of recruiting patients with pre-existing bladder cancer in clinical trials and may delay the final diagnosis. Of the nine dapagliflozin-treated patients with bladder cancer, eight had microscopic hematuria prior to start of treatment or within 6 months of initiating study treatment. Conclusion: The assessment of bladder cancer data illustrates the challenges of characterizing cancer risk in T2DM drug development programs. The totality of evidence to date does not suggest a causal relationship between dapagliflozin and bladder cancer. Funding: AstraZeneca.",
keywords = "Bladder cancer, Dapagliflozin, Hematuria, SGLT2 inhibitor, Type 2 diabetes mellitus",
author = "Agata Ptaszynska and Cohen, {Samuel Monroe} and Messing, {Edward M.} and Reilly, {Timothy P.} and Eva Johnsson and Kristina Johnsson",
year = "2015",
month = "9",
day = "26",
doi = "10.1007/s13300-015-0128-9",
language = "English (US)",
volume = "6",
pages = "357--375",
journal = "Diabetes Therapy",
issn = "1869-6953",
publisher = "Springer Publishing Company",
number = "3",

}

TY - JOUR

T1 - Assessing Bladder Cancer Risk in Type 2 Diabetes Clinical Trials

T2 - the Dapagliflozin Drug Development Program as a ‘Case Study’

AU - Ptaszynska, Agata

AU - Cohen, Samuel Monroe

AU - Messing, Edward M.

AU - Reilly, Timothy P.

AU - Johnsson, Eva

AU - Johnsson, Kristina

PY - 2015/9/26

Y1 - 2015/9/26

N2 - Introduction: Dapagliflozin, a sodium-glucose co-transporter 2 inhibitor, decreases plasma glucose levels by suppressing renal glucose reabsorption and increasing urinary glucose excretion. Previously published pre-clinical data suggest that dapagliflozin lacks carcinogenic potential. This article reviews data on bladder cancer with dapagliflozin to illustrate the challenges in assessing bladder cancer in drug development programs in patients with type 2 diabetes mellitus (T2DM). Methods: Clinical cases of bladder cancer were analyzed in a pooled population of >9000 patients in 21 phase 2b/3 dapagliflozin clinical trials of up to 208 weeks’ duration. Results: In the 21-study pool, demographic and baseline characteristics were generally consistent between dapagliflozin and comparator groups. The overall incidence of malignancies was also balanced between the treatment groups, with an incidence rate ratio (IRR) of 1.035 [95% confidence interval (CI): 0.724, 1.481]. Nine of 5936 dapagliflozin-treated patients and 1 of 3403 comparator-treated patients reported bladder cancer, with an IRR of 5.168 (95% CI: 0.677, 233.55). All of these patients had clinical attributes typical of bladder cancer in the general population (≥60-year-old males; 8 of the 10 patients were current/former smokers). All cases of bladder cancer were reported within 2 years of starting study treatment. There was an absence of detailed workup of hematuria prior to randomization, and no hematuria workup data were collected proactively in the dapagliflozin trials, which is typical of clinical practice. Failure to exclude bladder cancer prior to randomization increases the chance of recruiting patients with pre-existing bladder cancer in clinical trials and may delay the final diagnosis. Of the nine dapagliflozin-treated patients with bladder cancer, eight had microscopic hematuria prior to start of treatment or within 6 months of initiating study treatment. Conclusion: The assessment of bladder cancer data illustrates the challenges of characterizing cancer risk in T2DM drug development programs. The totality of evidence to date does not suggest a causal relationship between dapagliflozin and bladder cancer. Funding: AstraZeneca.

AB - Introduction: Dapagliflozin, a sodium-glucose co-transporter 2 inhibitor, decreases plasma glucose levels by suppressing renal glucose reabsorption and increasing urinary glucose excretion. Previously published pre-clinical data suggest that dapagliflozin lacks carcinogenic potential. This article reviews data on bladder cancer with dapagliflozin to illustrate the challenges in assessing bladder cancer in drug development programs in patients with type 2 diabetes mellitus (T2DM). Methods: Clinical cases of bladder cancer were analyzed in a pooled population of >9000 patients in 21 phase 2b/3 dapagliflozin clinical trials of up to 208 weeks’ duration. Results: In the 21-study pool, demographic and baseline characteristics were generally consistent between dapagliflozin and comparator groups. The overall incidence of malignancies was also balanced between the treatment groups, with an incidence rate ratio (IRR) of 1.035 [95% confidence interval (CI): 0.724, 1.481]. Nine of 5936 dapagliflozin-treated patients and 1 of 3403 comparator-treated patients reported bladder cancer, with an IRR of 5.168 (95% CI: 0.677, 233.55). All of these patients had clinical attributes typical of bladder cancer in the general population (≥60-year-old males; 8 of the 10 patients were current/former smokers). All cases of bladder cancer were reported within 2 years of starting study treatment. There was an absence of detailed workup of hematuria prior to randomization, and no hematuria workup data were collected proactively in the dapagliflozin trials, which is typical of clinical practice. Failure to exclude bladder cancer prior to randomization increases the chance of recruiting patients with pre-existing bladder cancer in clinical trials and may delay the final diagnosis. Of the nine dapagliflozin-treated patients with bladder cancer, eight had microscopic hematuria prior to start of treatment or within 6 months of initiating study treatment. Conclusion: The assessment of bladder cancer data illustrates the challenges of characterizing cancer risk in T2DM drug development programs. The totality of evidence to date does not suggest a causal relationship between dapagliflozin and bladder cancer. Funding: AstraZeneca.

KW - Bladder cancer

KW - Dapagliflozin

KW - Hematuria

KW - SGLT2 inhibitor

KW - Type 2 diabetes mellitus

UR - http://www.scopus.com/inward/record.url?scp=84942312400&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942312400&partnerID=8YFLogxK

U2 - 10.1007/s13300-015-0128-9

DO - 10.1007/s13300-015-0128-9

M3 - Article

C2 - 26323372

AN - SCOPUS:84942312400

VL - 6

SP - 357

EP - 375

JO - Diabetes Therapy

JF - Diabetes Therapy

SN - 1869-6953

IS - 3

ER -